A patient-led initiative for rare disease hereditary haemorrhagic telangiectasia (HHT) has won the inaugural Prix Galien Patient First Award, which recognises projects that "meaningfully integrate ...

Dojolvi was approved in the US in 2020 and was also launched in Japan earlier this year. Ultragenyx recorded sales of $45 ...

Marcus Evans today announced the Evolution Summit 2027, an invitation-only gathering of senior clinical trial executives, taking place 19-20 January 2027 at the Four Seasons Hotel. The Summit will ...

The WuXi agreement gives Fresenius "full strategic flexibility" to choose which biosimilar candidates to develop and gives ...

Hutchmed and AstraZeneca's Orpathys is now under review in Europe and Japan for MET-driven, EGFR-mutated lung cancer, a few ...

On 3 and 4 December 2026, Florence will host ISMAI 2026, the International Symposium on Medical AI, organised by the ...

Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid) has been granted an accelerated approval by the FDA as a ...

As the only dedicated forum convening the global liquid biopsy community, the 11th Liquid Biopsy for Precision Oncology ...

AbbVie has filed for FDA approval of its T-cell engager (TCE) etentamig in relapsed or refractory multiple myeloma, a key pillar of its strategic expansion into oncology. The drug, described as a ...

Against all the odds, Roche's Genentech unit has won FDA approval for its clot-busting drug TNKase as a treatment for acute ischaemic stroke, after all but abandoning the project a couple of years ago ...

Sanofi bids to add a drug candidate for Alzheimer's disease to its neurology pipeline via the acquisition of US biotech Vigil Neuroscience in a deal valued at $470 million. The $8-per-share deal will ...

Boehringer Ingelheim's alliance with digital health company Brainomix on an AI-enabled tool for diagnosing interstitial lung diseases (ILDs) has been broadened with a large-scale, prospective clinical ...